TrialThe oncologist2017

Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.

Ghassan K Abou-Alfa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.